Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-07-12 07:59 | English | 1.1 MB | |||
| 2012-07-02 07:59 |
Orexo tar ett stort kliv framåt i arbetet att hjälpa personer beroende av smärt…
|
Swedish | 99.8 KB | ||
| 2012-07-02 07:59 |
Orexo takes large step forward on the road to improve treatment for people depe…
|
English | 102.2 KB | ||
| 2012-06-29 15:29 |
Antal aktier och röster i Orexo
|
Swedish | 23.6 KB | ||
| 2012-06-29 15:29 |
Number of shares and votes in Orexo
|
English | 27.3 KB | ||
| 2012-06-19 08:29 |
Orexo successfully completes OX219 dose proportionality study ahead of schedule
|
English | 113.0 KB | ||
| 2012-06-19 08:29 |
Orexos OX219 dosproportionalitetstudie framgångsrikt slutfört snabbare än plane…
|
Swedish | 97.8 KB | ||
| 2012-06-18 14:00 |
Orexo rapporterar att Edluar® är godkänd för registrering i Europa
|
Swedish | 101.6 KB | ||
| 2012-06-18 14:00 |
Orexo reports regulatory approval of Edluar® in Europe
|
English | 104.1 KB | ||
| 2012-06-14 09:59 |
Kallelse till extra bolagsstämma i Orexo
|
Swedish | 128.4 KB | ||
| 2012-06-14 09:59 |
Notice of Extraordinary General Meeting of Orexo
|
English | 129.5 KB | ||
| 2012-06-04 08:05 |
Orexo acquires all US rights for Abstral and receives a net cash consideration …
|
English | 44.6 KB | ||
| 2012-06-04 08:05 |
Orexo förvärvar samtliga USA-rättigheter för Abstral och erhåller 610 MSEK
|
Swedish | 59.9 KB | ||
| 2012-05-25 10:00 |
Abstral EU success continues. Orexo receives sales milestone of 3.3 MEUR.
|
English | 29.8 KB | ||
| 2012-05-25 10:00 |
Abstrals framgångar i EU fortsätter. Orexo får delmålsbetalning på 3,3 MEUR.
|
Swedish | 47.6 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
